A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum
- PMID: 28577900
- DOI: 10.1016/j.imlet.2017.05.015
A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum
Abstract
Background: Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder. The characteristic episodes of subcutaneous/submucosal edema formation may be preceded by erythema marginatum (EM) - the occurrence of a 'map-like' pattern on the skin. EM can occur as an isolated finding or accompanying a hereditary angiooedema (HAE) attack as well. Nevertheless, it is unknown whether a HAE attack can be prevented by the proper prophylactic treatment during EM.
Objectives: Our aim was to assess the prevalence of EM in the Hungarian C1-INH-HAE population and to introduce a safe and effective novel prophylactic treatment during EM in patients who's HAE attacks are preceded by EM in a considerable proportion of the cases.
Results: Based on the data of the Hungarian HAE Registry, 49 among 173 C1-INH-HAE patients (28.3%) from 32 families had EM in their life. According to the clinical data and the patient's HAE diaries, two patients (Patient #1, Patient #2) were selected who frequently had EM as a prodromal symptom. Both patients were instructed to administer plasma-derived C1-inhibitor concentrate (pdC1-INH) as soon as possible after the onset of EM, in order to prevent the development of HAE attack. Interestingly, HAE attacks never developed if pdC1-INH was administered within 6h from the occurrence of EM in both patients. In contrast, without pdC1-INH treatment, in Patient 1 and Patient 2, 97.0% and 44.3% of the EM were followed by a HAE attack, respectively (p<0.0001, Fisher's exact test).
Conclusions: As a novel prophylaxis in C1-INH-HAE, intravenous administration of pdC1-INH concentrate during EM might be an effective, individual therapeutic strategy in those patients who's HAE attacks are often preceded by EM. Besides it can improve the quality of life of these selected patients, pdC1-INH administration during EM provides the lowest effective dose for the prophylaxis of their HAE attacks.
Keywords: C1-inhibitor deficiency; Erythema marginatum; Hereditary angioedema; Individualized prophylactic therapy; Prodromal symptom.
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Changes of coagulation parameters during erythema marginatum in patients with hereditary angioedema.Int Immunopharmacol. 2020 Apr;81:106293. doi: 10.1016/j.intimp.2020.106293. Epub 2020 Feb 17. Int Immunopharmacol. 2020. PMID: 32078942
-
Survey of actual conditions of erythema marginatum as a prodromal symptom in Japanese patients with hereditary angioedema.World Allergy Organ J. 2021 Feb 6;14(2):100511. doi: 10.1016/j.waojou.2021.100511. eCollection 2021 Feb. World Allergy Organ J. 2021. PMID: 33643518 Free PMC article.
-
Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2379-2383. doi: 10.1016/j.jaip.2020.02.043. Epub 2020 Mar 17. J Allergy Clin Immunol Pract. 2020. PMID: 32198128
-
The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.Postgrad Med. 2021 Aug;133(6):639-650. doi: 10.1080/00325481.2021.1905364. Epub 2021 Jul 6. Postgrad Med. 2021. PMID: 33993830 Review.
-
Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.Immunotherapy. 2014;6(5):533-51. doi: 10.2217/imt.14.33. Epub 2014 Mar 17. Immunotherapy. 2014. PMID: 24635050 Review.
Cited by
-
The analysis of the effect of the COVID-19 pandemic on patients with hereditary angioedema type I and type II.Sci Rep. 2023 Nov 22;13(1):20446. doi: 10.1038/s41598-023-47307-1. Sci Rep. 2023. PMID: 37993569 Free PMC article.
-
Prodromes predict attacks of hereditary angioedema: Results of a prospective study.Allergy. 2023 Feb;78(2):577-579. doi: 10.1111/all.15556. Epub 2022 Oct 29. Allergy. 2023. PMID: 36259763 Free PMC article. No abstract available.
-
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.Orphanet J Rare Dis. 2019 Mar 13;14(1):65. doi: 10.1186/s13023-019-1043-3. Orphanet J Rare Dis. 2019. PMID: 30866985 Free PMC article.
-
Pathways of Neutrophil Granulocyte Activation in Hereditary Angioedema with C1 Inhibitor Deficiency.Clin Rev Allergy Immunol. 2021 Jun;60(3):383-395. doi: 10.1007/s12016-021-08847-4. Epub 2021 Feb 19. Clin Rev Allergy Immunol. 2021. PMID: 33606193 Free PMC article.
-
C1-inhibitor Deficiency Induces Myositis-like Symptoms Via the Deposition of the Membrane Attack Complex in the Muscle.Intern Med. 2020 Sep 1;59(17):2173-2176. doi: 10.2169/internalmedicine.4601-20. Epub 2020 May 26. Intern Med. 2020. PMID: 32461528 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous